Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Sawyer, Elizabeth B ^a   Edgeworth, Julie Ann ^a,b   Thomas, Claire ^a   Collinge, John ^a   Jackson, Graham S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Human Tissue Authority   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MMP9 PROTEIN, MOUSE; PRION;

ANIMAL; BLOOD; BLOOD BRAIN BARRIER; BLOOD EXAMINATION; CREUTZFELDT JAKOB DISEASE; INBRED MOUSE STRAIN; INCUBATION TIME; LIMIT OF DETECTION; LUMINESCENCE; MESOCRICETUS; PRION; PRION DISEASE; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; BLOOD-BRAIN BARRIER; CREUTZFELDT-JAKOB SYNDROME; HEMATOLOGIC TESTS; INFECTIOUS DISEASE INCUBATION PERIOD; LIMIT OF DETECTION; LUMINESCENT MEASUREMENTS; MATRIX METALLOPROTEINASE 9; MESOCRICETUS; MICE, INBRED STRAINS; MICE, TRANSGENIC; PRION DISEASES; PRIONS;

EID: 84949256542     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17742     Document Type: Article

References (50)

1. Prusiner, S. B. Prions. Proc Natl Aca Sci USA 95, 13363-13383 (1998).
2. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24, 519-550 (2001).
3. Hill, A. F. et al. The same prion strain causes vCJD and BSE. Nature 389, 448-50, 526 (1997).
4. Gill, O. N. et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 347, f5675 (2013).
5. Garske, T. & Ghani, A. C. Uncertainty in the Tail of the Variant Creutzfeldt-Jakob Disease Epidemic in the UK. PLoS One 5, e15626 (2010).
6. Collinge, J. et al. Kuru in the 21st century-An acquired human prion disease with very long incubation periods. Lancet 367, 2068-2074 (2006).
7. Houston, F. et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 112, 4739-4745 (2008).
8. McCutcheon, S. et al. All Clinically-Relevant Blood Components Transmit Prion Disease following a Single Blood Transfusion: A Sheep Model of vCJD. PLoS One 6, e23169 (2011).
9. Andreoletti, O. et al. Highly efficient prion transmission by blood transfusion. PLoS Pathog 8, e1002782 (2012).
10. Llewelyn, C. A. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363, 417-421 (2004).
11. Peden, A. H., Head, M. W., Ritchie, D. L., Bell, J. E. & Ironside, J. W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364, 527-529 (2004).
12. Wroe, S. J. et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368, 2061-2067 (2006).
13. Gregori, L. A prototype assay to detect vCJD-infected blood. Lancet 377, 444-446 (2011).
14. Halliez, S. et al. White blood cell-based detection of asymptomatic scrapie infection by ex vivo assays. PLoS One 9, e104287 (2014).
15. Segarra, C. et al. Plasminogen-Based Capture Combined with Amplification Technology for the Detection of PrP(TSE) in the Pre-Clinical Phase of Infection. PLoS One 8, e69632 (2013).
16. Lacroux, C. et al. Preclinical Detection of Variant CJD and BSE Prions in Blood. PLoS Pathog 10, e1004202 (2014).
17. Chandler, R. L. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet 1, 1378-1379 (1961).
18. Edgeworth, J. A., Jackson, G. S., Clarke, A. R., Weissmann, C. & Collinge, J. Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces. Proc Natl Acad Sci USA 106, 3479-3483 (2009).
19. Edgeworth, J. A. et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 377, 487-493 (2011).
20. Jackson, G. S. et al. Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test: Diagnostic Accuracy and Feasibility Study. JAMA Neurol 71, 340 (2014).
21. Fischer, M. et al. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 15, 1255-1264 (1996).
22. Edgeworth, J. A. et al. Spontaneous generation of mammalian prions. Proc. Natl. Acad. Sci. USA 107, 14402-14406 (2010).
23. Saa, P., Castilla, J. & Soto, C. Presymptomatic detection of prions in blood. Science 313, 92-94 (2006).
24. Saa, P. et al. First demonstration of PrPTSE in extracellular vesicles from plasma of mice infected with mouse-adapted variant Creutzfeldt-Jakob disease by in vitro amplification of misfolded prion protein. J Biol Chem. 289, 29247-29260 (2014).
25. Brown, P. et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 38, 810-816 (1998).
26. Brown, P. et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 39, 1169-1178 (1999).
27. Cervenakova, L. et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 43, 1687-1694 (2003).
28. Gregori, L. et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 364, 529-531 (2004).
29. Waubant, E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers 22, 235-244 (2006).
30. Benesova, Y. et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult. Scler 15, 316-322 (2009).
31. Chandler, S. et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72, 155-161 (1997).
32. Opdenakker, G., Nelissen, I. & Van Damme, J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2, 747-756 (2003).
33. Peden, A. et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 16, 296-304 (2010).
34. Parliamentary Questions. 16 May 2011. http://www.publications.parliament.uk/pa/cm201011/cmhansrd/cm110516/text/110516 w0003.htm.
35. Jackson, G. S. et al. A highly specific blood test for vCJD. Blood 123, 452-453 (2014).
36. Zanusso, G., Bongianni, M. & Caughey, B. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med 371, 1842-1843 (2014).
37. Moda, F. et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med 371, 530-539 (2014).
38. Duncan, R. E. et al. Ethical considerations in presymptomatic testing for variant CJD. J Med Ethics 31, 625-630 (2005).
39. Tattum, M. H., Jones, S., Pal, S., Collinge, J. & Jackson, G. S. Discrimination between prion-infected and normal blood samples by protein misfolding cyclic amplification. Transfusion 50, 996-1002 (2010).
40. Elder, A. M. et al. In Vitro Detection of prionemia in TSE-Infected Cervids and Hamsters. PLoS One 8, e80203 (2013).
41. Klohn, P., Stoltze, L., Flechsig, E., Enari, M. & Weissmann, C. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci USA 100, 11666-11671 (2003).
42. Mahal, S. P., Demczyk, C. A., Smith, E. W., Jr., Klohn, P. C. & Weissmann, C. Assaying Prions in Cell Culture: The Standard Scrapie Cell Assay (SSCA) and the Scrapie Cell Assay in End Point Format (SCEPA). Methods Mol Biol 459, 49-68 (2008).
43. Sandberg, M. K., Al Doujaily, H., Sharps, B., Clarke, A. R. & Collinge, J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470, 540-542 (2011).
44. Sandberg, M. K. et al. Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nat Commun 5, 4347 (2014).
45. Kaplan, A. et al. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron 81, 333-348 (2014).
46. Safar, J. G. et al. Prion clearance in bigenic mice. J Gen Virol 86, 2913-2923 (2005).
47. Peretz, D. et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743 (2001).
48. Goold, R. et al. Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun 2, 281 (2011).
49. Orru, C. D. et al. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. MBio. 2, e00078-11 (2011).
50. Cronier, S. et al. Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin. Biochem J 416, 297-305 (2008).